New Zealand’s Medicinal Cannabis Agency has approved several adjustments to the Medicinal Cannabis Scheme, aiming to foster economic growth and research within the industry. Although these changes are primarily technical, they include expanding the definitions of plant-based medicine categories, adjusting export quality criteria for easier market access, and permitting licenses for non-therapeutic plant research. Introduced in April 2020, the Scheme’s intent was enhancing patient access to quality plant-based medicine products. Chris James, Deputy Director-General Regulatory Services at Manatū Hauora, highlights the importance of supporting local production for both domestic and export markets, and fostering scientific research to drive innovation.
Information about studies provided by Cannatrek on this website is for education purposes only. It is not a substitute for professional health advice. Nothing contained in this site, or any external site linked to by Cannatrek, is intended to be used as medical advice and it is not intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes or as a substitute for your own health professional’s advice. Cannatrek does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information provided on this website, or any external site linked to by Cannatrek. Further, Cannatrek accepts no responsibility for material contained in a website that is linked to this site. It is the responsibility of the user to make their own decisions about the accuracy, currency, reliability and correctness of information contained in linked external websites.